The role of adipocyte products in progress of insulin resistance in obese and hypertensive patients;Udział produktów adipocytów w rozwoju insulinooporności u pacjentów z otyłościa̧ i nadciśnieniem tȩtniczym

Nadcisnienie Tetnicze

Volumn 8, Issue 1, 2004, Pages 33-40

  Szulínska, Monika ^a   Pupek Musialik, Danuta ^a   Bogdański, Paweł ^a  

^a Katedra i Klinika Ftyzjopneumonologii   (Poland)

Author keywords

Adiponectin; Adipose tissue; Insulin resistance; Leptin; Resistin adiponectin; TNF

Indexed keywords

ADIPONECTIN; INSULIN; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN METABOLISM; INSULIN RESISTANCE; OBESITY; PATHOGENESIS; REVIEW;

EID: 1942488972     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. The World Health Report 2002. Reducing Risks, Promoting Health Life, Genewa 2002.
2. Zdrojewski T., Szpakowski P., Bandosz P. i wsp. Rozpowszechnienie głównych czynników ryzyka sercowo-naczyniowego w Polsce w 2002 roku. Wyniki badania NATPOL III Plus. Kardiologia Polska 2003; 59 (supl. 1): 235.
3. Larimore J.W. A study of blood pressure in relation to type on bodily habitus. Arch. Intern. Med. 1923; 31: 567-572.
4. Higgins M., Kannel W., Garrison R., Pinsky J., Stokes J.I. Hazards of obesity: the Framingham experience. Acta Med. Scand. 1988; 723: 23-36.
5. Rocchini A.P., Katch V., Schork A., Kelch R.P. Insulin and blood pressure during weight loss in obese adolescents. Hypertension 1987; 10: 267-273.
6. Van Itallie T.B. The problem of obesity: health implications of overweight and obesity. Ann. Intern. Med. 1985; 103: 983-988.
7. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The INC 7 Report JAMA 2003; 289: 2560-2571.
8. Selby J.V., Friedman G.D., Quesenberry C.P. Precursors of essential hypertension. The role of body fat distribution pattern. Am. J. Epidemiol. 1989; 129: 43-53.
9. Siani A., Cappuccio F., Barba G. i wsp. The relationship of waist circumference to blood pressure: the Olivetti heart study. Am. J. Hypertens. 2002; 15: 780-786.
10. Flegal K., Carroll M., Ogden C., Johnson C. Prevalence and Trends in Obesity Among US Adults, 1999-2000. JAMA 2002; 288: 1723-1727.
11. Rossner S. Obesity: the disease of the twenty-first century. Int. J. Obes. 2002; 26: 2-4.
12. Rywik S., Broda G., Piotrowski W. i wsp. Epidemiologia chorób układu kra̧zenia. Program Pol-Monica Warszawa. Kardiologia Polska 1996; 44 (supl. II): 7-35.
13. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., Dietz W.H. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
14. Report of a WHO. Consultation on Obesity. Obesity. Preventing and Managing the Global Epidemic. Division of noncommunicable Diseases. WHO. Genewa 3-5 czerwca 1997.
15. De Fronzo R.A. Lilly lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
16. Natali A., Sontoro D., Palombo C., Cerri M., Ghione S., Ferrannini E. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991; 17: 170-178.
17. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
18. Stern M.P. The insulin resistance syndrome. W: International text book of diabetes mellitus. Albert K.G. (red.). Wyd 2: John Wiley, Chichester 1995; 255-283.
19. Feskens E.J., Loeber J.G., Kromhout D. Diet and physical activity on determinant of hiperinsulinemia: the Zutphen Elderly Study. Am. J. Epidemiol. 1994; 140: 350-360.
20. Shimamoto K., Hirata A., Fukuoka M. i wsp. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23 (supl. I): 29-33.
21. Capaldo B., Lembo G., Napoli R. i wsp. Skeletal muscle is a primary site of insulin resistance in essential hypertension. Metabolism 1991; 40: 1320-1322.
22. Shulman G.I., Rothman D.L., Jue T., Stein P., De Fronzo RA., Shulman R.G. Quantitation of muscle glycogen synthesis in normal subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonanse spectroscopy. N. Engl. J. Med. 1990; 322: 223-228.
23. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: A novel mechanism for insulin resistance. J. Clin. Invest. 1990; 85: 1844-1852.
24. De Fronzo R.A., Cooke C.R., Andres R., Faloona G.R., Davis P.J. The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J. Clin. Invest. 1975; 55: 845-847.
25. Roden M., Price T.B., Perseghin G., Petersen K.F., Rothman D.L. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 1996; 97: 2859-2865.
26. Schonsjans K., Staels B., Auverx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochem. Biophys. Acta 1996; 1302: 93-109.
27. Kahn A.M., Seidel C.L., Allen J.C., Oneil R.G., Shelat H., Song T. Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle. Hypertension 1993; 22: 735-742.
28. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle mechanisms induced by lipid oversupply. Cellular Signalling 2000; 12: 583-594.
29. Krook A., Orahilly S. Mutant insulin receptors in syndromes of insulin resistance. Baillieres Clin. Endocrinol. Metab. 1996; 10: 97-122.
30. Lichtenstein A.H., Schwabu S. Relationship of dietary fat to glucose metabolism. Atherosclerosis 2000; 150: 227-243.
31. Serrero G., Lepak N. Endocrine and paracrine negative regulators of adipose differentiation. Int. J. Obes. 1996; 20: 58-64.
32. Fruhbeck G., Gomez-Ambrosi J., Jose Muruzabal F., Burrell M. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001; 280: 827-847.
33. Hotamisligil G.S. Increased adipose tissue expression of tumor necrosis factor-alfa in human obesity and insulin resistance. J. Clin. Invest. 1995; 95: 2409-2415.
34. Saghizadeh M. The expression of TNF-alfa by human muscle. Relationship to insulin resistance. J. Clin. Invest. 1996; 97: 1111-1116.
35. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
36. Uysal K., Wiesbrock S., Marino M. Hotamisligil G. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
37. Hotamisligil G., Arner P., Caro J., Atkinson K., Spiegelman B. Increased adipose expression of tumor necrosis factor-a in human obesity and insulin resistance. J. Clin. Invest. 1995, 95, 2409-2415.
38. Bullo-Bonet M., Garcia-Lorca P., Lopez-Soriano F., Argiles I., Salas-Salvado J. Tumor necrosis factor, a key role in obesity? FEBS Letters 1999; 451: 215-219.
39. Aggarwal B., Natarajan K. Tumor necrosis factor: developments during the last decade. Eur. Cytokin. Netw. 1996; 7: 93-124.
40. Tsigos C., Kyrou I., Chala E. i wsp. Circulating Tumor Necrosis Factor Alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999; 48: 1332-1335.
41. Bogdafiski P., Pupek-Musialik D., Łuczak M., Bryl W., Jabłecka A. Czynnik martwicy nowotworów w procesie indukcji insulinooporności u osób z otyłościa̧ prosta̧. Diabetologia Doświadczalna i Kliniczna 2002; 2: 449-454.
42. Dzienis-Stra̧czkowska S., Staczkowski M., Szelachowska M., Stȩpień A., Kowalska I., Kinalska I. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care 2003; 26: 875-880.
43. Lang C.H., Dobrescu C., Bagby G.J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130: 43-52.
44. Liu L., Spelleken M., Rohirg K., Hauner H., Eckel J. Tumor necrosis factor-alpha acutely inhibits insulin sygnaling in human adipocytes: implication of p80 tumor necrosis factor receptor. Diabetes 1998; 47: 515-522.
45. Hotamisligil G., Murray D., Choy L., Spiegelman B. TNF-alpha inhibits signaling from insulin receptor. Proc. Natl. Acad. Sci. USA 1994; 91: 4854-4858.
46. Hotamisligil G., Peraldi P., Budavari A., Ellis R., White M., Spiegelman B. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science 1996; 271: 665-668.
47. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
48. De Paoli-Roach A.A., Suzuki Y., Lanner C. i wsp. Glycose PPIG. Diabetes 1999; 48: 25.
49. Dresner A. Effects of free fatty acid on glucose transport and IRS-1-associated phosphatidyloinositol 3-kinase activity. J. Clin. Invest. 1999; 103: 253-259.
50. Pan D.A. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46: 983-988.
51. Oakes N.D. Diet-induced muscle insulin resistance is ameliorated by acute dietary lipid withdrawal or a singel bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 1997; 46: 2022-2028.
52. Ferrannini E., Haffner S.M., Stern M.P. i wsp. High blood pressure and insulin resistance: influence of ethnic background. Eur. J. Clin. Invest. 1991; 21: 280-287.
53. Friedman J., Halaas J. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
54. Tartaglia L., Dembski M., Weng X. i wsp. Identyfication and expression cloning of a leptin receptor OB-R. Cell 1995; 83: 1263.
55. Considine R.V. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996; 334: 292-295.
56. Fruhbeck G., Salvador J. Relation between leptin and the regulation of glucose metabolism. Diabetol. 2000; 43: 3-12.
57. Heymsfield S.B. Recombinant leptin for weight loss in obese and lean adults. A randomised, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575.
58. Bastard I.P. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 2000; 85: 3338-3342.
59. Steppan C.M., Bailey S.T., Bhat S. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
60. Nagaev I., Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Comm. 2001; 561-564.
61. Scherer P.E. i wsp. A novel serum protein similar to Clq, produced exclusively in adipocytes. J. Biol. Chem. 1995; 270: 267.
62. Kubota N. i wsp. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002; 277: 25863-25866.
63. Weyer C. i wsp. Hypoadiponectinemiain obesity and type 2 diabetes: close association with insulin resistance and hiperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86: 1930.
64. Yamauchi T. i wsp. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001; 7: 941.
65. Fruebis J. i wsp. Proteolitic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. PNAS 2001; 98: 2005.
66. Weyer C., Funahashi T., Tanakas i wsp. Hipoadiponectinemia in obesity and type 2 diabetes. Close association with insulin resistance and hyperinsulinemia. J. Clin. Endoc. and Metab. 2001; 86: 1930-1935.